VAI-SU2C Epigenetics Dream Team

11 results.

October 10, 2024 Disrupting Asxl1 gene prevents T-cell exhaustion, improving immunotherapy

MEMPHIS, Tenn. (Oct. 10, 2024) — Immunotherapy, using a patient’s own immune system to treat disease, has shown promise in some patients with cancer but…

March 27, 2024 Combining epigenetic cancer medications may have benefit for colorectal cancers and other tumor types

GRAND RAPIDS, Mich. (March 27, 2024) — A pair of medications that make malignant cells act as if they have a virus could hold new promise for…

August 3, 2023 Making an impact in the real-world: Five things to know about the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team

Since October 2014, the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team has supported and launched breakthrough clinical trials that explore potential new…

November 1, 2022 Combining two cancer medications may increase survival in relapsed myelodysplastic syndrome, lays groundwork for future cancer therapies

GRAND RAPIDS, Mich. (Nov. 1, 2022) — A pair of cancer medications that act as a one-two punch against malignant cells demonstrated increased survival in…

April 4, 2019 Blocking epigenetic “Swiss army knife” may be a new strategy for treating colorectal cancer

GRAND RAPIDS, Mich. (April 4, 2019) — A new study out today in Cancer Cell shows that blocking specific regions of a protein called…

May 9, 2018 Fighting cancer is a team effort

Four years ago, we embarked on a collaborative endeavor to improve cancer treatment by establishing the Van Andel Research Institute–Stand Up To Cancer (VARI–SU2C) Epigenetics…

December 21, 2017 10 highlights: A look back at 2017

With 2017 quickly coming to close, we’d like to reflect on all that’s been accomplished by rounding up some of this year’s most notable stories…

October 12, 2017 Stand Up To Cancer awards $5.5 million to VARI for cancer clinical trials to enhance immunotherapy

GRAND RAPIDS, Mich. (Oct. 12, 2017)—Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team (VARI-SU2C) scientists have been awarded two…